The use of mineralocorticoid antagonists in chronic heart failure

The use of mineralocorticoid antagonists in chronic heart failure

For the treatment of chronic heart failure, the 2021 and 2023 guidelines of the European Society of Cardiology (ESC) provide clear recommendations for optimal pharmacological therapy in heart failure with reduced (HFrEF), mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). Mineralocorti...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Szegedi, Nóra Homoródi, Attila Borbély
Format: Article
Language:English
Published: Promenade Kft 2025-07-01
Series:Cardiologia Hungarica
Subjects:
heart failure with reduced ejection fraction
renin-angiotensin-aldosterone system
eplerenone
finerenone
Online Access:https://cardiologia.hungarica.eu/archive/2025-issues/2025-3-contents/the-use-of-mineralocorticoid-antagonists-in-chronic-heart-failure
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://cardiologia.hungarica.eu/archive/2025-issues/2025-3-contents/the-use-of-mineralocorticoid-antagonists-in-chronic-heart-failure

Similar Items